Krish Patel (@krishpatelmd) 's Twitter Profile
Krish Patel

@krishpatelmd

Director #lymphoma #Research @SarahCannonDocs @SCRIOncology #Duke alum x4. Foodie. Dad of 2. Husband. Tweets my own, not medical advice. #cll #lymsm

ID: 2173316471

calendar_today08-11-2013 12:54:29

359 Tweet

897 Takipçi

326 Takip Edilen

VJHemOnc (@vjhemonc) 's Twitter Profile Photo

Tanya Siddiqi (City of Hope | Orange County), Krish Patel (Providence Swedish), and Alexey Danilov (City of Hope, Danilov Lab) sat down to discuss highlights from a session on novel therapies. They focused on BTK inhibitors and degraders. The full discussion is coming soon to

Tanya Siddiqi (<a href="/cityofhopeoc/">City of Hope | Orange County</a>), <a href="/KrishPatelMD/">Krish Patel</a> (<a href="/ProvSwedish/">Providence Swedish</a>), and Alexey Danilov (<a href="/cityofhope/">City of Hope</a>, <a href="/DanilovLab/">Danilov Lab</a>) sat down to discuss highlights from a session on novel therapies. 

They focused on BTK inhibitors and degraders. The full discussion is coming soon to
VJHemOnc (@vjhemonc) 's Twitter Profile Photo

Watch our roundtable discussion from #iwNHL2024, to hear about all things bispecifics in #NonHodgkinLymphoma from leading experts Stephen Ansell, MariSubklewe, Martin Hutchings, & Krish Patel: 👉 ow.ly/LneY50TJIgB 👈 #LYMsm #Lymphoma #ImmunoOnc #HemOnc

VJHemOnc (@vjhemonc) 's Twitter Profile Photo

Interested in hearing about BTK inhibitors in MCL?🩸 Check out our podcast! Featuring Krish Patel, Michael Wang, MD, Marek Trneny, and Craig Portell. 🎧Listen here: ow.ly/tzKj50TY9e2 #LYMsm #Lymphoma #HemOnc

Interested in hearing about BTK inhibitors in MCL?🩸

Check out our podcast! Featuring <a href="/KrishPatelMD/">Krish Patel</a>, <a href="/michaelwangmd/">Michael Wang, MD</a>, <a href="/MarekTrnenyDr/">Marek Trneny</a>, and Craig Portell. 

🎧Listen here: ow.ly/tzKj50TY9e2

#LYMsm #Lymphoma #HemOnc
Alan Skarbnik (@askarbnik) 's Twitter Profile Photo

Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL ashpublications.org/bloodadvances/… It was awesome to collaborate with great colleagues and friends on this! Thanks Lymphoma Research Foundation for the support. Deborah Stephens

Vivek Subbiah, MD (@viveksubbiah) 's Twitter Profile Photo

🌟 Exciting News! 🌟 So thrilled to announce a significant milestone for our early-phase drug development program at Sarah Cannon Research Institute (SCRI) Sarah Cannon Docs ⭐️We are proud to welcome Mary Crowley Cancer Research, a leader in early-phase clinical research based in

🌟 Exciting News! 🌟
So thrilled to announce a significant milestone for our early-phase drug development program at Sarah Cannon Research Institute (SCRI) <a href="/SarahCannonDocs/">Sarah Cannon Docs</a> 
⭐️We are proud to welcome Mary Crowley Cancer Research, a leader in early-phase clinical research based in
Rémy Duléry (@remydulery) 's Twitter Profile Photo

Happy to share our work published in Nature Medicine! We analyzed 3,066 patients from the French DESCAR-T registry who received #CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%). nature.com/articles/s4159…

SCRI Oncology Partners (@scrioncology) 's Twitter Profile Photo

🎉 Today we celebrate National Women Physician Day! At Sarah Cannon Docs, we're proud of the incredible women leading groundbreaking research & advancing cancer care. Your dedication inspires us every day- thank you! ❤️ 👩‍⚕️ #WomenInMedicine #NationalWomenPhysicianDay #oncology

AmericanJournalofHematology (@ajhematology) 's Twitter Profile Photo

#TP53 abnormalities are the main prognostic marker of mantle cell #lymphoma & cannot be replaced by any other MIPI marker. First-line treatment is evolving with BTK inhibitor-based therapies. To assess risk of early relapse, test for TP53 mutations by NGS. doi.org/10.1002/ajh.27…

#TP53 abnormalities are the main prognostic marker of mantle cell #lymphoma &amp; cannot be replaced by any other MIPI marker. First-line treatment is evolving with BTK inhibitor-based therapies. To assess risk of early relapse, test for TP53 mutations by NGS.
doi.org/10.1002/ajh.27…
PeerView (@peerview) 's Twitter Profile Photo

“Targeted Strategies, Cellular Therapy, and HCT in B-Cell Cancers” with Krish Patel, MD (Krish Patel), and Nirav Shah, MD, MS (Nirav Shah). 3/20 at 7 PM EDT. bit.ly/CLL-MCL-25T #CLL #MCL

“Targeted Strategies, Cellular Therapy, and HCT in B-Cell Cancers” with Krish Patel, MD (<a href="/KrishPatelMD/">Krish Patel</a>), and Nirav Shah, MD, MS (<a href="/niravshahmd/">Nirav Shah</a>). 3/20 at 7 PM EDT. bit.ly/CLL-MCL-25T #CLL #MCL
VJHemOnc (@vjhemonc) 's Twitter Profile Photo

🚨 New podcast alert! 🎧 Dive into the latest strategies in treating R/R MCL with BTK inhibitors, combo therapies, & overcoming resistance. Featuring experts Krish Patel, Yucai Wang, MD, PhD, Julie Vose, Adrian Minson, & David Lewis. Listen now! 👇 ow.ly/tERo50Vnn9V

🚨 New podcast alert! 🎧 

Dive into the latest strategies in treating R/R MCL with BTK inhibitors, combo therapies, &amp; overcoming resistance. 

Featuring experts <a href="/KrishPatelMD/">Krish Patel</a>, <a href="/YucaiWangMD/">Yucai Wang, MD, PhD</a>, <a href="/DrJulieVose/">Julie Vose</a>, <a href="/AdrianMinson/">Adrian Minson</a>, &amp; David Lewis. Listen now! 👇
ow.ly/tERo50Vnn9V
Benjamin Garmezy (@bgarmezy) 's Twitter Profile Photo

Looking forward to it! Excited to discuss outpatient cellular therapy/T cell engage therapy and how to manage the side effects. Leaning on experience from Sarah Cannon Docs and Krish Patel as well!

VJHemOnc (@vjhemonc) 's Twitter Profile Photo

We're thrilled to bring you some fantastic content from #iwCART25!💉🩸 In an exclusive discussion, Krish Patel, Danilov Lab, and Tycel Phillips share updates on the progress of #CARTCell therapy & bispecific antibodies in #lymphoma: 🎥 ow.ly/6GlJ50VKiT4 #LYMsm #HemOnc

PeerView (@peerview) 's Twitter Profile Photo

CLL Community Conversations on Modern Care: Participate in a dynamic #PeerView TownHall and engage in meaningful dialogue on real-world challenges in #CLL care. 5/31 at 6:30 PM CDT. Produced w/ @CLLSociety. bit.ly/CLL-25T #ASCO25 Nitin Jain Meghan Thompson Krish Patel

CLL Community Conversations on Modern Care: Participate in a dynamic #PeerView TownHall and engage in meaningful dialogue on real-world challenges in #CLL care. 5/31 at 6:30 PM CDT. Produced w/ @CLLSociety. bit.ly/CLL-25T #ASCO25 <a href="/NitinJainMD/">Nitin Jain</a> <a href="/MCThompsonMD/">Meghan Thompson</a> <a href="/KrishPatelMD/">Krish Patel</a>
CLL Society Inc. (@cllsociety) 's Twitter Profile Photo

Navigating new options in #CLL care? Join us and PeerView at #ASCO25 for an interactive TownHall featuring expert insights on BTK inhibitors, CAR-T, and personalized strategies! Learn more at bit.ly/CLL-25T Nitin Jain Krish Patel Meghan Thompson

Navigating new options in #CLL care? Join us and <a href="/PeerView/">PeerView</a> at #ASCO25 for an interactive TownHall featuring expert insights on BTK inhibitors, CAR-T, and personalized strategies!
 Learn more at bit.ly/CLL-25T
 <a href="/NitinJainMD/">Nitin Jain</a> <a href="/KrishPatelMD/">Krish Patel</a> <a href="/MCThompsonMD/">Meghan Thompson</a>
PeerView (@peerview) 's Twitter Profile Photo

🎥 Hear from Dr. Krish Patel as he shares what to expect at PeerView’s TownHall symposium on #CLL care during #ASCO25! Join him, Nitin Jain, Meghan Thompson & CLL Society Inc. for this interactive session on 5/31. 📍 Grand Ballroom B, Hyatt Chicago 🔗 bit.ly/CLL-25T

Binaytara (@binaytara) 's Twitter Profile Photo

Join the CME/ACPE-accredited 2025 Seattle Cellular Therapy Summit, where leading experts deliver insights on CAR T therapies, lymphoma management, and breakthrough strategies for hematologic malignancies. Register NOW: buff.ly/eJkilhc